SEASTAR MEDICAL HOLDING CORPORATION - COMMON STOCK

Economic Analysis Supporting Significant Hospitalization Cost Reduction with SeaStar Medical’s QUELIMMUNE Pediatric Therapeutic Device Presented at ASN Kidney Week 2024 - Update

25 10 2024 10:32:00 提供 Nasdaq GlobeNewswire

Economic Analysis Supporting Significant Hospitalization Cost Reduction with SeaStar Medical’s QUELIMMUNE Pediatric Therapeutic Device Presented at ASN Kidney Week 2024

25 10 2024 07:30:00 提供 Nasdaq GlobeNewswire

SeaStar Medical Announces that Stanford Medicine is Cleared to Actively Enroll Subjects in the Adult Acute Kidney Injury Pivotal Trial

23 10 2024 07:30:00 提供 Nasdaq GlobeNewswire

SeaStar Medical to Distribute QUELIMMUNE Directly to Hospital Customers

22 10 2024 07:30:00 提供 Nasdaq GlobeNewswire

SeaStar Medical Announces that Enrollment in its Adult Acute Kidney Injury Pivotal Trial Has Exceeded the Halfway Point Toward an Interim Analysis

18 10 2024 07:30:00 提供 Nasdaq GlobeNewswire

SeaStar Medical to Showcase New Mechanistic Data Highlighting the Immunomodulatory Effect of the Selective Cytopheretic Device in Acute Kidney Injury at ASN Kidney Week

15 10 2024 07:30:00 提供 Nasdaq GlobeNewswire

SeaStar Medical to Present at the 2024 Maxim Healthcare Virtual Summit

09 10 2024 07:30:00 提供 Nasdaq GlobeNewswire

SeaStar Medical Expands NEUTRALIZE-AKI Pivotal Trial Adding Two Premier Military Medical Facilities

08 10 2024 07:30:00 提供 Nasdaq GlobeNewswire

SeaStar Medical Reports Enrollment Momentum in Its Pivotal Adult AKI Trial

25 9 2024 07:30:00 提供 Nasdaq GlobeNewswire

SeaStar Medical to Webcast Fireside Chat at the H.C. Wainwright Global Investment Conference

05 9 2024 07:00:00 提供 Nasdaq GlobeNewswire

SeaStar Medical Strengthens Financial Position with Elimination of All Long-Term Debt

04 9 2024 07:30:00 提供 Nasdaq GlobeNewswire

SeaStar Medical Reports Second Quarter 2024 Financial Results and Provides a Business Update

13 8 2024 15:38:00 提供 Nasdaq GlobeNewswire

First Pediatric Patient Treated in a Commercial Setting with SeaStar Medical’s FDA-Approved QUELIMMUNE Therapeutic Device

23 7 2024 07:30:00 提供 Nasdaq GlobeNewswire

CMS Grants Category B Coverage for Adults with Acute Kidney Injury Enrolled in SeaStar Medical’s Selective Cytopheretic Device Pivotal Trial

16 7 2024 07:30:00 提供 Nasdaq GlobeNewswire

SeaStar Medical Ships First QUELIMMUNE Product Order to U.S. Distribution Partner

12 7 2024 07:30:00 提供 Nasdaq GlobeNewswire

SeaStar Medical Announces Closing of $10 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

11 7 2024 15:05:00 提供 Nasdaq GlobeNewswire